

Witold B Rybka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7370494/publications.pdf>

Version: 2024-02-01

35
papers

675
citations

840776

11
h-index

580821

25
g-index

36
all docs

36
docs citations

36
times ranked

1352
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. <i>Blood Advances</i> , 2022, 6, 1232-1242.	5.2	14
2	Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant. <i>Journal of Hematology and Oncology</i> , 2022, 15, 64.	17.0	24
3	A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E46-E50.	4.1	16
4	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
5	Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion. <i>Annals of Hematology</i> , 2021, 100, 2585-2592.	1.8	2
6	Engraftment Kinetics and Recipient Chimerism Increase to Predict Leukemia Relapse By Ptcy and Non-Ptcy Transplant. <i>Blood</i> , 2021, 138, 1792-1792.	1.4	0
7	Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML. <i>British Journal of Haematology</i> , 2020, 188, 674-684.	2.5	12
8	A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2191-2199.	1.3	4
9	Eomes+T-betlow CD8+ T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid Leukemia. <i>Cancer Research</i> , 2019, 79, 1635-1645.	0.9	42
10	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 362-368.	2.0	40
11	Non-Myeloablative Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia: Graft-Versus-Host Disease Potentiates Graft-Versus-Leukemia Effect and Improves Overall Survival. <i>Blood</i> , 2019, 134, 5724-5724.	1.4	0
12	VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML. <i>Oncolimmunology</i> , 2018, 7, e1469594.	4.6	107
13	Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2216-2223.	2.0	18
14	Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. <i>Blood Cancer Journal</i> , 2018, 8, 34.	6.2	48
15	TIGIT Expression Positively Associates with NK Cell Function in AML Patients. <i>Blood</i> , 2018, 132, 5250-5250.	1.4	5
16	Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML. <i>Blood</i> , 2018, 132, 1526-1526.	1.4	13
17	Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 124.	17.0	42
18	PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features. <i>Oncotarget</i> , 2017, 8, 29887-29905.	1.8	9

#	ARTICLE	IF	CITATIONS
19	T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients. <i>Clinical Cancer Research</i> , 2016, 22, 3057-3066.	7.0	217
20	The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 1792-1792.	1.4	5
21	A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti-T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2016, 128, 505-505.	1.4	12
22	A Phase I Dose Finding Trial of Eltrombopag during Consolidation Therapy in Adults with Acute Myeloid Leukemia Employing a Unique Dosing Design: PrE0901, a Precog Study. <i>Blood</i> , 2016, 128, 4053-4053.	1.4	1
23	Phase I/II Study of Clofarabine, Etoposide, and Mitoxantrone in Patients With Refractory or Relapsed Acute Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 41-46.	0.4	9
24	Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902. <i>Blood</i> , 2015, 126, 1308-1308.	1.4	7
25	Unrelated donor umbilical cord blood transplantation with and without total body irradiation: A single-center experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18001-e18001.	1.6	0
26	R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission. <i>Blood</i> , 2012, 120, 676-676.	1.4	2
27	Early Discharge and Out Patient Management After AML Induction Chemotherapy: Determinants of Safety. <i>Blood</i> , 2012, 120, 2054-2054.	1.4	0
28	Clofarabine, Etoposide and Mitoxantrone In the Therapy of Relapsed and Refractory Acute Myelogenous Leukemia. <i>Blood</i> , 2010, 116, 4353-4353.	1.4	17
29	Tipifarnib Is Well Tolerated as Maintenance Therapy In Acute Myeloid Leukemia (AML). Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary Results of the Phase III Intergroup Trial E2902. <i>Blood</i> , 2010, 116, 3315-3315.	1.4	1
30	Survival Among Lymphoma Patients Over the Past Three Decades: A Single Institution Based Retrospective Review From 1976 to 2006.. <i>Blood</i> , 2009, 114, 4527-4527.	1.4	2
31	Long Term Survival After Sirolimus Based Non-Ablative Alternative Donor Transplantation.. <i>Blood</i> , 2009, 114, 1212-1212.	1.4	0
32	Survival Among Leukemia Patients Over the Past Three Decades: A Single Institution Based Retrospective Review From 1976 to 2006.. <i>Blood</i> , 2009, 114, 1394-1394.	1.4	0
33	Sirolimus as Primary Immunoprophylaxis for Alternative Donor Allotransplant after Non-Myeloablative Conditioning.. <i>Blood</i> , 2007, 110, 3069-3069.	1.4	0
34	Non-Myeloablative Hematopoietic Transplant with Sirolimus Immunosuppression: Determinants of Outcome.. <i>Blood</i> , 2005, 106, 5462-5462.	1.4	0
35	Successful Treatment of Advanced and Refractory AML with Sirolimus Based Non-Myeloablative Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 2760-2760.	1.4	0